The Cold Chain Problem: Why Your Probiotic Might Be Dead Before You Buy It

Industry Analysis · 13 min read

✓ Our Investigations Desk — July 31, 2026

By The dogsupplementreport.com Investigations Team · Updated July 2026

By Sarah Jennings, Regulatory Correspondent  |  Published July 30, 2026  |  14 min read

Table of Contents

• The Problem No One Talks About
• Why Live Bacteria Are Fragile
• The Journey From Factory to Food Bowl
• Delivery Method vs. Stability Risk
• The “At Manufacture” Fine Print
• The Postbiotic Alternative
• Our Findings
• Frequently Asked Questions
• References

The Problem No One Talks About

The number is printed in large, confident type on the front of the package:^[1] 30 Billion CFU. It looks like a guarantee. It is, in fact, a snapshot — and a stale one.

That number describes how many live bacteria were in the product at the moment it left the factory. It does not describe how many are alive today, sitting in a warehouse, a delivery truck, or a mailbox in the summer sun. It does not describe how many will survive the journey through your dog’s stomach acid. And it does not describe how many will arrive, alive and active, in the place they are supposed to work.

The core finding of this investigation: The entire value proposition of a live probiotic rests on organisms staying alive across a supply chain that is, by its nature, hostile to them. The published literature shows that a large and unpredictable fraction does not survive — and that the number on the label is frequently not the number in the product^[2].

This is the cold chain problem, and it is the single most under-discussed vulnerability in the multi-billion-dollar probiotic segment^[6]. It is not a matter of a few bad brands. It is a consequence of the biology of live organisms and the physics of getting a product from a manufacturing floor to a dog in a hot climate. Understanding it changes how you read every probiotic label.

Why Live Bacteria Are Fragile

A probiotic, by definition, contains^[3] live microorganisms. That is what distinguishes it from other supplement categories — and it is precisely what makes it fragile. Living cells are sensitive to their environment in ways that, say, a mineral or a vitamin is not.

The peer-reviewed literature identifies four principal killers:

• Heat. Elevated temperature accelerates bacterial die-off. This is the dominant risk in a supply chain that routinely passes through un-air-conditioned warehouses and parked delivery trucks.
• Moisture. Water activity drives degradation. Soft chews — the most popular probiotic format, accounting for the large majority of the market by some estimates — introduce moisture that works against shelf stability.
• Oxygen. Many probiotic strains, including bifidobacteria, are sensitive to oxygen exposure, which degrades them over time^[4].
• Time. Even under good conditions, viability declines across a product’s shelf life, which can run 12 to 24 months^[5].

The International Scientific Association of Probiotics and Prebiotics (ISAPP) has noted plainly that over a shelf life of 12 to 24 months at room temperature, “a proportion of cells will likely lose viability.” This is not a defect. It is the expected behavior of living things.

The Journey From Factory to Food Bowl

Now follow a bottle of probiotics from the factory to your dog. At each stage, the organisms are exposed to conditions that reduce the count.

Manufacturing

The manufacturing process itself — mixing, drying, compression into chews or tablets — can stress or kill a portion of the culture. Heat generated during processing is a particular concern for live organisms.

Warehousing

Finished goods sit in warehouses that are not, in general, refrigerated. In warm regions and warm months, ambient temperatures inside storage facilities can climb well into the range that accelerates die-off. A product may sit for weeks or months before it ships.

Shipping and last-mile delivery

This is where the “cold chain” — the unbroken sequence of temperature-controlled handling that a live product ideally requires — most often breaks. Standard e-commerce shipping is not refrigerated. Packages ride in hot trucks, sit on sun-baked porches, and bake in mailboxes. A product labeled to require refrigeration may spend days in transit without it. Our broader look at how ingredients and products move, our supply chain investigation, documents how little visibility consumers have into these conditions.

The stomach

Even a product that survives the shelf must then survive the dog. Gastric acid is hostile to bacteria. A 2023 study of microencapsulated canine-specific probiotics found that even protected cells showed one- to two-log reductions in viable count after 180 minutes in simulated gastric juice — and unprotected cells fared far worse. In other words, the final gauntlet claims a large share of whatever made it this far.

Delivery Method vs. Stability Risk

Not all delivery methods carry the same risk. The table below summarizes our assessment — an editorial assessment based on the published literature — of the stability risk associated with the principal ways biotics reach a dog.

Risk ratings are an editorial assessment based on the cited literature, not the result of our own stability testing. Individual products vary with formulation, packaging, and handling.

The “At Manufacture” Fine Print

Here is the part most consumers miss. When a label prints a CFU count, that number typically reflects potency at the time of manufacture. Some labels specify “at expiration,” but many do not — and the difference can be enormous.

The industry’s standard response to die-off is a practice called overfilling. ISAPP has observed that manufacturers commonly overfill probiotic capsules or sachets with 1.5 to 4 times more live cells than the label states, to compensate for the organisms expected to die during shelf life. Read that again: the number on the label is not the number in the product. The product contains a multiple of the labeled amount at the factory, precisely so that — after expected die-off — something close to the labeled amount might remain later. It is an engineering workaround for a biological problem, and it is an implicit acknowledgment that viability is a moving target.

Independent testing suggests the workaround often falls short. The findings are consistent and sobering:

• A landmark analysis of commercial veterinary probiotics found that only a minority of products with specific CFU claims met or exceeded their label claim, with quality control described as poor (Weese & Martin, 2011).
• A 2017 review in the Journal of the American Veterinary Medical Association reported that products containing live organisms showed actual concentrations “ranging from 0.008% to 215% of the labeled concentrations,” and that all eight veterinary products evaluated in one study “contained concentrations for individual microorganisms that were <2% of label claims” (Jugan et al., 2017).
• An assessment of companion-animal kefir products found that every product with a guaranteed count overstated its microorganisms by at least tenfold (Metras et al., 2020).

Key Finding: The CFU number is the probiotic category’s headline selling point — and it is the metric least likely to be accurate by the time you buy. When independent labs check, the live count frequently bears little resemblance to the label. The number that matters is the number of organisms that arrive alive in your dog’s gut, and no label prints that one.

We examined the broader pattern of labels diverging from actual content in The Dosage Gap. The cold chain problem is that pattern’s biological cause.

The Postbiotic Alternative

There is a structural solution to the cold chain problem, and it is not better refrigeration. It is removing the fragility entirely.

A postbiotic is, per the 2021 ISAPP consensus definition, “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host” (Salminen et al., 2021). The key word is inanimate. The microorganisms have been inactivated — typically by heat — and what remains are the cell components and metabolites that do the biological work: cell-wall fragments, short-chain fatty acids, peptides, and other bioactive compounds.

Because there are no live cells to keep alive, the entire cold chain problem disappears. The literature is consistent on this point:

• Postbiotics are “more stable than live probiotics, which makes them less sensitive to temperature, light, and pH, making them easy to store and transport” (Hernández-Granados et al., 2024; PMC11321893).
• “Unlike live probiotics, which are sensitive to processing and environmental conditions… postbiotics are inherently more stable as they are composed of inanimate entities. Moreover, postbiotics do not rely on cold chain supply management” (PMC12639491, 2025).
• “Postbiotics do not require refrigeration, can survive heat processing, and pose no risk of infection or microbial imbalance” (PMC12639491, 2025).
• A storage-stability evaluation found that a postbiotic preparation “maintained the highest bioactivity when stored at 15–25°C,” supporting ambient-temperature storage (Arrioja-Bretón et al., 2020).

The practical consequence for a consumer is significant. A postbiotic delivers the same dose from the first sachet to the last, regardless of whether the package sat in a hot warehouse or a cold one. There is no overfilling required to hedge against die-off, because there is no die-off. There is no refrigeration to forget, no cold chain to break, no gamble about how many organisms survived the mailbox in July. The dose on the label is the dose in the product, consistently, across its shelf life.

The consumer product that embodies this stability argument is , whose formula uses a heat-treated (inactivated) postbiotic rather than live cultures — so there is no viable count to decay and no cold chain to break. Our assessment is in the spotlight below.

We want to be precise about what this does and does not establish. Stability is not the same as proven superiority. There are not yet head-to-head trials proving postbiotics outperform probiotics on health outcomes in dogs. What the evidence does establish is that postbiotics remove an entire category of uncertainty — the viability gamble — that live probiotics cannot escape. For a consumer who wants to know that what they are paying for is actually present and consistent, that is a meaningful, literature-supported advantage.

It is also, notably, an advantage that compounds with the others our investigations keep surfacing: the products built on postbiotic science tend to be the same ones that publish canine clinical trials and disclose every dose. The categories travel together. We explore the clinical-evidence side in The Clinical Trial Gap.

Related Investigations

• The Dosage Gap: Label Claims vs Actual Content in Dog Probiotics
• The $4.2 Billion Question: Why Most Supplements Have Zero Clinical Evidence
• The Clinical Trial Gap: Which Brands Actually Publish Research
• The Oral Health Blind Spot: Why Dog Supplements Ignore the Mouth